Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Huahai Investment Co., Ltd China

Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.
Website:
en.huahaipharm.com/
Company Size (Fulltime employees)
11-50
Partnering Objectives
Please specify your partnering goal
We are interested in investment and licensing deals with companies developing therapeutics in a wide variety of areas, including oncology, CNS diseases, ophthalmology, and infectious diseases.
Headquartner in China
Yes
Biotech/Pharma Category
Mr. Hanson Lo
Director, BD 
Functionality
Business Development

HUYA BIOSCIENCE INTERNATIONAL United States

Website:
www.huyabio.com
Partnering Objectives
Please specify your partnering goal
To find new projects of interest
Headquartner in China
No
Biotech/Pharma Category
Yung-Chih Wang
Senior Vice President, Corporate Development China 
金丽 杨
科学联络经理 
晓煊 胡
科学联络经理 
超骏 龚
科学联络经理 
Renfei WANG
Scientific liaison manager 

illumina China

Illumina is a provider of Next Generation Sequencing technology
Website:
www.illumina.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Leslie Lu
BD Manager 
Wei Zhang
senior clinical specialist 

Jemincare China

Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.

Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.

Website:
http://www.jmkx.com/en/
Company Size (Fulltime employees)
5000+
Year of foundation
1999
Partnering Objectives
Please specify your partnering goal
1) Seeking out-licensing opportunities for 6 innovative and differentiated assets (global excluding China); 2) Seeking in-licensing opportunities of late-stage assets (China)
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
JMKX0623 (NaV1.8 blocker)
Assets Information 2
JMKX1657 (selective AR degradation drug)
Assets Information 3
JMKX1899 (KRAS-G12C inhibitor)
Biotech/Pharma Asset Stage
Mrs. Lilian Peng
BD Manager 
Functionality
Business Development

Jiangsu Hengrui Medicine Co.,Ltd. China

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Website:
http://www.hrs.com.cn/company_summary.html
Company Size (Fulltime employees)
5000+
Year of foundation
50 years
Partnering Objectives
Please specify your partnering goal
In-licensing clinical stage assets for China market; out-licensing ex-China rights of Hengrui assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Please see the link below for our pipeline. Most of our assets are out-licensing candidates|https://www.hengruius.com/pipeline.html||China, US and global (please check with us for detailed info)
Ms. Linda Zhao
Head, US BD Team 
Functionality
Business Development

leaguer group

创业投资 园区服务一体化
Website:
www.leaguer.com.cn
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
laurent 高
specialist 

lianbio China

license-in paradigm shifting durgs to China patients
Website:
Www.lianbio.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
sylvie zhou
Sr director 

Merck United States

Biopharmaceutical
Website:
www.merck.com
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
NA
Headquartner in China
No
Biotech/Pharma Category
KONGQI YU
区域经理 
Dr. Min Lu
Assoc Principal Scientist 
Functionality
Research and Development

Mesa Verde Venture Partners United States

Life Sciences venture capital fund with three funds under management.
Website:
www.mesaverdevp.com
Company Size (Fulltime employees)
1-10
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
Meeting investors and potential companies
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
not applicable|||
Mr. Randy Berholtz
Senior Advisor 
Functionality
Management

Micar Innovation (Micar21) Bulgaria

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET.

Website:
Micar Innovation (Micar21)
Company Size (Fulltime employees)
11-50
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Drug Discovery Collaborations
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 939.67KB)
Mr. DIMITAR DIMITROV
LinkedIn logo CEO 
Functionality
Management